Salud financiera de hoja de balance de PharmaCyte Biotech

Salud financiera controles de criterios 6/6

PharmaCyte Biotech tiene un patrimonio de los accionistas total de $54.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $71.4M y $17.2M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$61.21m
Patrimonio	US$54.18m
Total pasivo	US$17.18m
Activos totales	US$71.36m

Actualizaciones recientes sobre salud financiera

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($61.5M) de PMCB superan a sus pasivos a corto plazo ($2.2M).

Pasivo a largo plazo: Los activos a corto plazo de PMCB ($61.5M) superan a sus pasivos a largo plazo ($14.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PMCB está libre de deudas.

Reducción de la deuda: PMCB no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PMCB tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: PMCB tiene suficiente cash runway para más de 3 años si el flujo de caja libre sigue creciendo a tasas históricas de 3.2% cada año

Salud financiera de hoja de balance de PharmaCyte Biotech

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech Common Stock Deleted from Other OTC

Recent updates

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera